The interesting six-jurisdiction patent case between two of the world’s leading enzyme manufacturers, the Danish companies Danisco A/S (now part of DuPont) and Novozymes A/S has already been subject to earlier blogs both here and several times on EPLAW and PatLit. To recap the story briefly, Novozymes started the proceedings by applying for a preliminary…

The objection raised by the opponent that the protected subject matter of a divisional application extends beyond the content of the parent application does not represent a “fresh ground for opposition”,. This bbecause in the present case i.c. the opposition division hadhas earlier raised an unrelated objection earlier, holdinstating that the patent based on the…

In the decision T 1621/09 of the Boards of Appeal of the EPO, it was decided that late filed arguments of the appellant amended the case to such an extent that their admittance lay within the Board’s discretion, even though the new arguments were based on facts and evidence already in the proceedings. Having found so the Board, exercising its discretion, did not admit the new arguments into the proceedings.

On 20 March 2012, the Tribunal de Grande Instance of Paris rendered its decision in the case relating to raloxifene, a molecule useful for treating or preventing osteoporosis in post-menopausal women, opposing Teva to Eli Lilly. This decision raises many questions, first concerning drug patents in particular (patentability of second medical use, patentability of the resolution of…

The Polish Supreme Administrative Court has recently recognized a contradiction between the decisions of the Polish Patent Office regarding computer-implemented inventions and the practice of the European Patent Office (EPO). However, it is too early to say for certain whether Polish administrative courts have definitely changed their approach to so-called software patents. In a recent…